Evaluation of Outcomes in Metastatic Gastric and Esophageal Carcinoma in Relation to Immunotherapy


About this study

The purpose of this study is:

  • To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal carcinoma through retrospective chart review.
  • To explore if response to checkpoint inhibitors is dependent on biomarkers on tumor tissue.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults (Age 18 or more years) with a diagnosis of metastatic gastric and esophageal carcinoma

Exclusion Criteria: 

  • Patients with incomplete record or if pre-treatment tissue is not available for analysis

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Harry Yoon, M.D.

Open for enrollment

Contact information:

Sakti Chakrabarti M.B.B.S.

(715) 735-6523


More information


Publications are currently not available

Mayo Clinic Footer